Safety profile and efficacy of secukinumab in the treatment of autoimmune myasthenia gravis: a single-center retrospective study
Secukinumab demonstrated rapid and sustained clinical benefits in AChR+ gMG, linked to suppression of the Th17/IL-17 pathway. These findings highlight IL-17 inhibition as a promising targeted strategy for MG. Limitations include small sample size and retrospective design, warranting validation in larger randomized trials.
Authors
- Zhaoxu Zhang (ORCID: https://orcid.org/0000-0002-7702-9915)
- Shuangmei Zhang
- An Wang (ORCID: https://orcid.org/0000-0003-2822-9061)
- Xiaodong Song (ORCID: https://orcid.org/0000-0002-4574-2054)
Institutions
- Chinese Academy of Sciences (CN)
- Peking University (CN)
- Zhejiang Cancer Hospital (CN)
- Peking University People's Hospital (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Cancer Hospital of Chinese Academy of Medical Sciences (CN)
- Shandong Provincial QianFoShan Hospital (CN)
- Shandong First Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.3389/fneur.2025.1642938
- Citations
- 1
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- National Natural Science Foundation of China
- Shandong First Medical University